Relevant agencies predict that by 2040, the number of people under the age of 50 will further decrease, the number of people over the age of 60 and over 80 will rise sharply, and the number of over-aged people (people over 80) will increase from 12 million in 2000. It will increase to more than 40 million by 2030, and the number of elderly people over 65 will also increase from the current 115 million to about 240 million by 2030.
In this period of deepening social aging, increasing national living standards, expanding medical insurance coverage, and increasing demand for interventional surgery, the demand for high-value medical consumables will also increase significantly.
It is understood that medical consumables refer to the frequently consumed accessory products used in hospitals and are the material basis for medical work. According to the price point, medical consumables can be divided into low-value consumables and high-value consumables. Medical high-value consumables are mainly relatively low-value consumables, which are mainly suitable for medical specialty treatment. Cardiac intervention products based on cardiac stents, peripheral vascular intervention and orthopedic implants are the main types of high-value medical consumables. .
Because medical high-value consumables are mainly interventional and implantable consumables, which require direct contact with the human body, they generally have higher risks. Therefore, the industry's barriers to entry and technology have always been high, and companies entering the field in the short term cannot grow and grow rapidly.
This has led to the fact that, in addition to the localization of some products such as stents and bio-patches, most of China's high-value consumables market is surrounded by foreign companies, mainly Johnson & Johnson, Medtronic, Abbott, Stryker and others. With its high-tech level, it has occupied the main market of the high-end market. In order to improve this situation, in recent years, relevant national departments have been giving preferential policies to the realization of import substitution in the field of high-value medical consumables. Since 2012, the state has been promoting "Healthy China" and "Made in China 2025", and has issued a series of related policies to support the development of domestic high-value medical consumables.
At present, with the encouragement of policies and the increasing market demand for domestic high-value medical consumables, domestic equipment manufacturers are increasing their R & D investment in high-value medical consumables, and domestic equipment manufacturers are gradually increasing the research and development of high-value medical consumables. Put in. In recent years, domestic manufacturers such as Lepu Medical, Guanhao Bio, Zhenghai Bio, etc. have begun to make domestic products in the low-end and mid-end products.
Based on this, some insiders said that in the future, import substitution will become an important opportunity for domestic high-value medical consumables companies to increase their market share. And with the reform of public hospitals, the advancement of graded diagnosis and treatment and the development of private hospitals, high-value medical consumables, especially domestic orthopedic implantable consumables, will develop rapidly. In the context of increasingly stringent industry regulations, a large number of domestic non-standard small medical device channel vendors may also be eliminated quickly, and the industry restructuring will accelerate.